Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

NNC0194-0499 · NNC0194

Peptide · developed by Novo Nordisk

Phase 2 Most advanced trial (none active)
NVO Developer
1 Registered trials

What is NNC0194-0499?

NNC0194-0499 (also coded NNC0194) is a drug given subcutaneously. It is studied in alcohol-related liver disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NNC0194
Drug type
Peptide
Therapy area
Gastroenterology
Developer
Novo Nordisk A/S (NVO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06409130 Phase 2 Alcohol-related Liver Disease Completed NVO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alcohol-related Liver Disease

More from Novo Nordisk

Sources

Updated Nov 22, 2026. Something wrong or missing? Report it on the NVO page.

Follow NVO, the company behind NNC0194-0499

See NVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.